Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerability of ME-143, find the maximum
tolerated dose, and the safety profile in patients with refractory solid tumors.